Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
DRUG

Flecainide Acetate

oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

DRUG

Placebo

placebo, similar in appearance to flecainide

DRUG

Beta blocker

Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.

Trial Locations (10)

10010

NYU Langone Medical Center, New York

27705

Duke University, Durham

27834

East Carolina University, Greenville

37027

Vanderbilt University, Nashville

43205

Nationwide Children's Hospital, Columbus

44109

MetroHealth Medical Center, Cleveland

76104

Cook Children's Hospital, Fort Worth

84112

University of Utah, Salt Lake City

90095

University of California Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT01117454 - Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia | Biotech Hunter | Biotech Hunter